The discovery of pyrano[3,4-b]indole-based allosteric inhibitors of HCV NS5B polymerase with in vivo activity

ChemMedChem

Volumn 3, Issue 10, 2008, Pages 1508-1515

  LaPorte, Matthew G ^a   Jackson, Randy W ^b   Draper, Tandy L ^b   Gaboury, Janet A ^b   Galie, Kristin ^b   Herbertz, Torsten ^b   Hussey, Alison R ^b   Rippin, Susan R ^b   Benetatos, Christopher A ^b   Chunduru, Srinivas K ^b   Christensen, Joel S ^b   Coburn, Glen A ^b   Rizzo, Christopher J ^b   Rhodes, Gerry ^b   O'Connell, John ^c   Howe, Anita Y M ^c   Mansour, Tarek S ^c   Collett, Marc S ^b   Pevear, Daniel C ^b   Young, Dorothy C ^b   Gao, Tiejun ^d   Tyrrell, D Lorne J ^d,e   Kneteman, Norman M ^d,e   Burns, Christopher J ^b   Condon, Stephen M ^a   more..

^a TetraLogic Pharmaceuticals   (United States)

^b ViroPharma Incorporated   (United States)

^c Wyeth ^*  (United States)

^d KMT Hepatech Inc   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antiviral agents; HCV NS5B polymerase; Hepatitis C; Inhibitors; Pyranoindoles

Indexed keywords

ANTIVIRUS AGENT; INDOLE DERIVATIVE; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; PYRAN DERIVATIVE; RNA DIRECTED RNA POLYMERASE; VIRUS PROTEIN; VIRUS RNA;

ALLOSTERISM; ANIMAL; ARTICLE; BLOOD; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HEPATITIS C VIRUS; IC 50; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; MOUSE MUTANT; SYNTHESIS; TRANSGENIC MOUSE;

ALLOSTERIC REGULATION; ANIMALS; ANTIVIRAL AGENTS; HEPACIVIRUS; INDOLES; INHIBITORY CONCENTRATION 50; MICE; MICE, SCID; MICE, TRANSGENIC; PYRANS; RNA REPLICASE; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS;

EID: 54849404284     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200800168     Document Type: Article

References (60)

1. R. Bartenschlager, V. Lohmann, J. Gen. Virol. 2000, 81, 1631.
2. a) World Health Organization: Hepatitis C, Weekly Epidemiology Record 1997, 72, 65;
3. b) M. J. Alter, D. K. Moran, O. V. Nainan, G. M. McQullan, F. Geo, L. A. Moyer, R. A. Kaslow, H. S. Margolis, N. Engl. J. Med. 1999, 341, 556.
4. a) J. Cohen, Science 1999, 285, 26;
5. b) National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C: 2002, 1.
6. a) K. Hanazaki, Curr. Med. Chem.: Anti-Infect. Agents 2003, 2, 103;
7. b) G. M. Lauer, B. D. Walker, N. Engl. J. Med. 2001, 345, 41;
8. c) G. Idéo, A. Bellobuono, Curr. Pharm. Des. 2002, 8, 959;
9. d) A. M. Di Bisceglie, J. McHutchison, C. M. Rice, Hepatology 2002, 35, 224;
10. e) C. E. Samuel, Clin. Microbiol. Rev. 2001, 14, 778.
11. For a recent medicinal chemistry perspective on HCV, See: C. P. Gordon, P. A. Keller, J. Med. Chem. 2005, 48, 1.
12. S.-L. Tan, A. Pause, Y. Shi, N. Sonenberg, Nat. Rev. Drug Discovery 2002, 1, 867.
13. a) S. Youngster, Y.-S. Want, M. Grace, J. Bausch, R. Bordens, D. F. Wyss, Curr. Pharm. Des. 2002, 8, 2139;
14. b) M. P. Manns, J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, k. Koury, M.-H. Ling, J. K. Albrecht, Lancet 2001, 358, 958;
15. c) J.-M. Pawlotsky, Business Briefing: US Gastroenter. Review, 2005, 75.
16. a) V. Lohmann, F. Körner, J.-O. Koch, U. Herian, L. Theilmann, R. Bartenschlager, Science 1999, 285, 110;
17. b) R. Bartenschlager, V. Lohmann, Antiviral Res. 2001, 52, 1;
18. c) For a recent review of HCV in vitro models, See: M. Régeard, C. Lepère, M. Trotard, P. Gripon, J. Le Seyec, FEBS J. 2007, 274, 4705.
19. D. F. Mercer, D. E. Schiller, J. F. Elliott, D. N. Douglas, C. Hao, A. Rinfret, W. R. Addison, K. P. Fischer, T. A. Churchill, J. R. T. Lakey, D. L. J. Tyrrell, N. M. Kneteman, Nat. Med. 2001, 7, 927.
20. N. M. Kneteman, A. J. Weiner, J. O'Connell, M. Collett, T. Gao, L. Aukerman, R. Kovelsky, Z.-J. Ni, A. Hashash, J. Kline, B. Hsi, D. Schiller, D. Douglas, D. L. J. Tyrrell, D. F. Mercer, Hepatology 2006, 43, 1346.
21. a) B. D. Lindenbach, P. Meuleman, A. Ploss, T. Vanwolleghem, A. J. Syder, J. A. McKeating, R. E. Lanford, S. M. Feinstone, M. E. Major, G. Leroux-Roels, C. M. Rice, Proc. Natl. Acad. Sci. USA 2006, 103, 3805;
22. b) B. D. Lindenbach, M. J. Evans, A. J. Syder, B. Wölk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, C. M. Rice, Science 2005, 309, 623;
23. c) J. Zhong, P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, F. V. Chisari, Proc. Natl. Acad. Sci. USA 2005, 102, 9294.
24. a) R. De Francesco, G. Migliaccio, Nature 2005, 436, 953;
25. b) D. Lamarre, P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bös, D. R. Cameron, M. Cartier, M. G. Cordingley, A. M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagacé, S. R. LaPlante, H. Narjes, M. A. Poupart, J. Rancourt, R. E. Sentjens, R. St. George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C. L. Yong, M. L. Brunet, Nature 2003, 426, 186;
26. c) R. B. Perni, S. J. Almquist, R. A. Byrn, G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, K. Dinehart, C. A. Gates, S. L. Harbeson, A. Heiser, G. Kalkeri, E. Kolaczkowski, K. Lin, Y. P. Luong, B. G. Rao, W. P. Taylor, J. A. Thomson, R. D. Tung, Y. Wei, A. D. Kwong, C. Lin, Antimicrob. Agents Chemother. 2006, 50, 899;
27. d) M. P. Manns, G. R. Foster, J. K. Rockstroh, S. Zeuzem, F. Zoulim, M. Houghton, Nat. Rev. Drug Discovery 2007, 6, 991;
28. e) E. De Clercq, Nat. Rev. Drug Discovery 2007, 6, 1001.
29. a) R. Bartenschlager, Antiviral Chem. Chemother. 1997, 8. 281;
30. b) M. W. Dymock, P. S. Jones, F. X. Wilson, Antiviral Chem. Chemother. 2000, 11, 79;
31. c) M. P. Walker, Z. Hong, Curr. Opin. Pharmacol. 2002, 22, 1;
32. d) J. Z. Wu, Z. Hong, Curr. Drug Targets 2003, 3, 207.
33. For recent reviews on HCV RNA RdRp inhibitors, see: a) S. M. Condon, M .G. LaPorte, T. Herbertz, Curr. Med. Chem.: Anti-Infect. Agents 2005, 4, 99;
34. b) R. De Francesco, L. Tomei, S. Tltamura, V. Summa, G. Migliaccio, Antiviral Res. 2003, 58, 1;
35. c) V. J.-P. Lévêque, Q. M. Wang, Cell. Mol. Life Sci. 2002, 59, 909.
36. a) Despite encouraging early clinical results of two leading HCV polymerase inhibitors (in combination with PEG- IFN), the compounds NM283 (Idenix) and HCV-796 (ViroPharma) have been dropped from development due to adverse side effects. www.idenix.com/press release, July 13, 2007 and http://www.viropharma.com/press release, August 10, 2007;
37. b) N. A. Meanwell, G. W. Koszalka, Curr. Opin. Invest. Drugs 2008, 9, 128.
38. a) A. Gopalsamy, K. Lim, G. Ciszewski, K. Park, J. W. Ellingboe, J. Bloom, S. Insaf, T. S. Mansour, G. Krishnamurthy, M. Damarla, Y. Pyatski, D. Ho, A. Y. M. Howe, M. Orlowski, B. Feld, J. O'Connell, J. Med. Chem. 2004, 47, 6603;
39. b) A. Gopalsamy, M. Collett, J. W. Ellingboe, M. G. LaPorte, T. Mansour, C. J. Burns, K. Park, S. M. Condon, PCT WO 099275, 2003.
40. a) A. Y. M. Howe, J. Bloom, C. J. Baldick, C. A. Benetatos, H. Cheng, J. S. Christensen, S. K. Chunduru, G. A. Coburn, B. Feld, A. Gopalsamy, W. P. Gorczyca, S. Herrmann, S. Johann, X. Jiang, M. L. Kimberland, G. Krisnamurthy, M. Olson, M. Orlowski, S. Swanberg, I. Thompson, M. Thorn, A. Del Vecchio, D. C. Young, M. van Zeijl, J. W. Ellingboe, J. Upeslacis, M. Collett, T. S. Mansour, J. F. O'Connell, Antimicrob. Agents Chemother. 2004, 48, 4813;
41. b) A. Y. M. Howe, H. Cheng, I. Thompson, S. K. Chunduru, S. Herrmann, J. O'Connell, A. Agarwal, R. Chopra, A. M. Del Vecchio, Antimicrob. Agents Chemother. 2006, 50, 4103.
42. R. W. Jackson; M. G. LaPorte, T. L. Draper, J. A. Gaboury, K. Galie, T. Herbertz, S. R. Rippin, C. A. Benetatos, S. K. Chunduru, D. C. Young, C. J. Burns, S. M. Condon, unpublished results.
43. nd National American Chemical Society Meeting, September 10 -14, San Francisco, CA, 2006, MEDI 240.
44. For a review of the Fischer indole reaction, see: D. L. Hughes, Org. Prep. Proced. Int. 1993, 25, 6, 609.
45. a) R. C. Larock, E. K. Yum, M. D. Refvik, J. Org. Chem. 1998, 63, 7652;
46. b) R. C. Larock, E. K. Yum, J. Am. Chem. Soc. 1991, 113, 6689.
47. Substituted indoles have been recently been prepared using similar reaction conditions: a) N. Gathergood, P. J. Scammells, Org. Lett. 2003, 5, 921;
48. b) X. Zhang, X. Li, J. C. Lanter, Z. Sui, Org. Lett. 2005, 7, 2043.
49. L. M. Cabral, P. R. R. Costa, M. L. A. A. Vasconcellos, E. J. Barreiro, R. N. Castro, Synth. Commun. 1996, 26, 3671.
50. J. E. De Los Angeles, V. I. Nikulin, G. Shams, A. A. Konkar, R. Mehta, D. R. Feller, D. D. Miller, J. Med. Chem. 1996, 39, 3701.
51. M. Woods, U. C. Dyer, J. F. Andrews, C. N. Morfitt, R. Valentine, J. Sanderson, Org. Process Res. Dev. 2000, 4, 418.
52. I. P. Lokot, F. S. Pashkovsky, F. A. Lakhvich, Tetrahedron 1999, 55, 4783.
53. At this point, the reason for the increased activities of these pyrazole containing compounds is not well understood.
54. T. Kato, T. Date, M. Miyamoto, A. Furusaka, K. Tokushige, M. Mizokami, T. Wakita, Gastroenterology 2003, 125, 1808.
55. B. Gu, A. T. Gates, O. Isken, S. E. Behrens, R. T. Sarisky, J. Virol. 2003, 77, 5352.
56. K. J. Blight, J. A. McKeating, J. Marcotrigiano, C. M. Rice, J. Virol. 2003, 77, 3181.
57. HCV genotype 1a was used for this investigation.
58. Cloning of the HCV NS5B polymerase isolated from the drug-treated animals revealed no changes to the NS5B primary sequence or any change to drug sensitivity indicating that pyranoindole-specific mutants were not readily selected during the course of the experiment.
59. Subsequent to our work, the activity of an unrelated HCV polymerase inhibitor in the chimpanzee model has been reported: C.-M. Chen, Y. He, L. Lu, H. B. Lim, R. L. Tripathi, T. Middleton, L. E. Hernandez, D. W. A. Beno, M. A. Long, W. M. Kati, T. D. Bosse, D. P. Larson, R. Wagner, R. E. Lanford, W. E. Kohlbrenner, D. Kempf, T. J. Pilot-Matias, A. Molla, Antimicrob. Agents Chemother. 2007, 51, 4290.
60. P. Cabildo, R. M. Claramunt, P. Cornago, J. L. Lavandera, D. Sanz, N. Jagerovic, M. L. Jimeno, J. Elguero, I. Gilles, J.-L. Aubagnac, J. Chem. Soc., Perkin Trans. 2 1996, 701.